Oramed Pharmaceuticals Statistics

Total Valuation

Oramed Pharmaceuticals has a market cap or net worth of ILS 360.59 million. The enterprise value is -224.69 million.

Market Cap	360.59M
Enterprise Value	-224.69M

Important Dates

The next estimated earnings date is Friday, November 8, 2024.

Earnings Date	Nov 8, 2024
Ex-Dividend Date	n/a

Share Statistics

Shares Outstanding	n/a
Shares Change (YoY)	+3.79%
Shares Change (QoQ)	+0.06%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	35.05M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.86
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	38.53

Financial Position

The company has a current ratio of 41.06, with a Debt / Equity ratio of 0.00.

Current Ratio	41.06
Quick Ratio	40.92
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	-0.31
Interest Coverage	-4.45

Financial Efficiency

Return on equity (ROE) is 12.70% and return on invested capital (ROIC) is -4.90%.

Return on Equity (ROE)	12.70%
Return on Assets (ROA)	-4.72%
Return on Capital (ROIC)	-4.90%
Revenue Per Employee	n/a
Profits Per Employee	19.64M
Employee Count	4
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +10,029.74% in the last 52 weeks. The beta is 1.76, so Oramed Pharmaceuticals's price volatility has been higher than the market average.

Beta (5Y)	1.76
52-Week Price Change	+10,029.74%
50-Day Moving Average	895.03
200-Day Moving Average	847.61
Relative Strength Index (RSI)	50.12
Average Volume (20 Days)	9,028

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.35

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-48.45M
Pretax Income	84.28M
Net Income	78.55M
EBITDA	-47.63M
EBIT	-48.45M
Earnings Per Share (EPS)	1.91

Full Income Statement

Balance Sheet

The company has 575.07 million in cash and 1.83 million in debt, giving a net cash position of 582.07 million.

Cash & Cash Equivalents	575.07M
Total Debt	1.83M
Net Cash	582.07M
Net Cash Per Share	n/a
Equity (Book Value)	663.24M
Book Value Per Share	16.41
Working Capital	563.02M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -5.69 million and capital expenditures -139,309, giving a free cash flow of -5.83 million.

Operating Cash Flow	-5.69M
Capital Expenditures	-139,309
Free Cash Flow	-5.83M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Oramed Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.79%
Shareholder Yield	-3.79%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Oramed Pharmaceuticals has an Altman Z-Score of 7.47.

Altman Z-Score	7.47
Piotroski F-Score	n/a